Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

Tze-Sian Chan,1,2 Chung-Chi Hsu,1,4 Vincent C. Pai,1,4 Wen-Ying Liao,4 Sheng-Shyang Huang,6 Kok-Tong Tan,7 Chia-Jui Yen,8 Shu-Ching Hsu,3 Wei-Yu Chen,3 Yan-Shen Shan,9 Chi-Rong Li,1 Michael T. Lee,10 Kuan-Ying Jiang,4 Jui-Mei Chu,4 Gi-Shih Lien,1,2 Valerie M. Weaver,11,12,13 and Kelvin K. Tsai1,4,8

1Graduate Institute of Clinical Medicine, College of Medicine, 2Laboratory of Advanced Molecular Therapeutics, Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, and 3Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan
2Laboratory for Tumor Aggressiveness and Stemness, National Institute of Cancer Research and 3National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan City 70456, Taiwan
3Graduate Program of Biotechnology in Medicine, Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan
4Department of Surgery, Tung’s Metro-Harbor Hospital, Taichung 45030, Taiwan
5Division of Hematology and Oncology, Department of Internal Medicine and 6Department of Surgery, National Cheng Kung University Hospital, Tainan 70403, Taiwan
6Department of Computer Science, Kun Shan University, Tainan 71003, Taiwan
7Department of Surgery, 8Department of Anatomy, and 9Department of Bioengineering and Therapeutic Sciences, Center for Bioengineering and Tissue Regeneration, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143

Although traditional chemotherapy kills a fraction of tumor cells, it also activates the stroma and can promote the growth and survival of residual cancer cells to foster tumor recurrence and metastasis. Accordingly, overcoming the host response induced by chemotherapy could substantially improve therapeutic outcome and patient survival. In this study, resistance to treatment was attributed to expansion of stem-like tumor-initiating cells (TICs) and metastasis has been associated with expansion of stromal cells. These experiments illustrate the importance of stroma in cancer therapy and how its impact on treatment resistance could be tempered by altering the dosing schedule of systemic chemotherapy.

INTRODUCTION

Solid human tumors such as breast cancer and pancreatic ductal adenocarcinoma (PDAC) are characterized by a pronounced stromal reaction termed the desmoplastic response that can promote tumor progression and invasion (Liootta and Kohn, 2001; Orimo et al., 2005; Karnoub et al., 2007; Shiao and Coussens, 2010). In desmoplastic tumors, carcinoma-associated fibroblasts (CAFs) are a major component of the stroma (Kalluri and Zeisberg, 2006; Erez et al., 2010), and these CAFs are not functionally inert but can foster tumor cell growth, survival, invasion, and even stemness by secreting paracrine factors, such as chemokines (Orimo et al., 2005; Erez et al., 2010), prostanoids (Rudnick et al., 2011), insulin-like growth factor (Chen et al., 2014), and proteases (Cheng et al., 2002) and by remodeling the extracellular matrix (Serebriiskii et al., 2008; Levental et al., 2009; Goetz et al., 2011). Importantly, both the tumor epithelium and adjacent stroma respond to systemic and local therapies, and a chemotherapy-modified stroma can deleteriously influence...
treatment efficacy (Nakasone et al., 2012; Sun et al., 2012). For instance, chemotherapy can stimulate the infiltration of tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and endothelial progenitor cells, and these chemo-modified stromal cells secrete inflammatory mediators and proteases, such as IL-1β, CXCR-4, cathepsin B, and matrix metalloproteinase 9, that can compromise therapeutic response (Shaked et al., 2008; Shiao and Coussens, 2010; Gingis-Velitski et al., 2011; Shree et al., 2011; Nakasone et al., 2012; Bruchard et al., 2013; Hughes et al., 2015; Voloshin et al., 2015). Chemotherapy can also enhance the expression of vascular endothelial growth factor on endothelial cells or induce the proliferation and extravasation of intravascular cancer cells and thereby paradoxically promote metastasis (Yamauchi et al., 2008; Daenen et al., 2011). CAFs also respond to chemotherapy, and such antitumor treatments can alter their functionality and endow them with the capacity to promote the malignant behavior of the treated tissue (Sonnenberg et al., 2008). Consistently, CAFs are enriched in chemotherapy-treated human tumor tissues, wherein they promote cancer growth and treatment resistance by secreting paracrine factors such as IL-17A, as was found in colon cancer, and Wnt 16B, as was observed in prostate cancer (Sun et al., 2012; Lotti et al., 2013). Such studies underscore the important role of CAFs in cancer therapy and suggest that targeting this component of the tumor stroma may provide a new avenue to improve the treatment outcome of human malignancies.

Traditional chemotherapy protocols involve the pulsatile administration of drugs to patients at their maximum-tolerated dose (MTD). By comparison, the potential benefit of using comparatively low doses of drug on a more frequent or continuous schedule in chemotherapy, a treatment modality termed low-dose metronomic (LDM) therapy, is slowly becoming appreciated (Kerbel and Kamen, 2004; Pasquier et al., 2010; Loven et al., 2013). Accumulating clinical evidence indicates that LDM chemotherapy offers equal if not better antitumor efficacy than traditional MTD regimens and at a lower accumulative dose of administered drug (Pasquier et al., 2010; Kerbel and Grothey, 2015). Nevertheless, the molecular mechanisms underlying the enhanced treatment response in LDM-treated patients remain poorly understood. In this respect, previous studies that have explored the origins of the enhanced antitumor efficacy of LDM chemotherapy primarily addressed its antiangiogenic effects (Kerbel and Kamen, 2004), such as direct cytotoxicity to endothelial cells (Bocci et al., 2002), reduced recruitment of endothelial progenitor cells and MDSCs into the tumors (Bertolini et al., 2003; Hasnis et al., 2014), and increased expression of the antiangiogenic factor thrombospondin-1 (Bocci et al., 2003). Recent studies suggest that LDM therapy may also mediate its antitumor effect by inhibiting regulatory T cells (Lusia et al., 2005; Ghiringhelli et al., 2007) and by triggering the maturation of tumor-infiltrating dendritic cells (Tanaka et al., 2009). Although compelling, these findings were obtained using subcutaneously injected human tumors and consequently were unable to address the impact of CAF–epithelial tumor interactions on the enhanced therapeutic efficacy observed using LDM therapy. Consequently, whether the increased efficacy of LDM treatment could be mediated through an altered CAF response and how remain unclear.

Tumors are highly heterogeneous and likely contain a subset of cancer cells termed tumor-initiating cells (TICs; Visvader and Lindeman, 2008). TICs are intrinsically more resistant to therapy and, consequently, increase disproportionately after systemic chemotherapy and are thought to contribute to tumor relapse and treatment resistance (Li et al., 2008; Visvader and Lindeman, 2008; Creighton et al., 2009). Accordingly, adjuvant strategies that temper the chemotherapy-induced enrichment of TICs could significantly improve the therapeutic outcome of cancer patients. In this regard, TICs exist in a dynamic equilibrium with their microenvironment such that their abundance is tightly regulated by cell–cell interactions and soluble secreted factors such as cytokines (te Poele et al., 2002; Calabrese et al., 2007; Beck et al., 2011; Iliopoulos et al., 2011; Korkaya et al., 2011, 2012). Given that CAFs are an abundant source of cytokines and chemokines and CAFs respond to chemotherapy, we asked whether the treatment-induced enrichment in TICs could be caused by enhanced paracrine signaling induced in CAFs after standard high-dose chemotherapy and whether this phenotype could be tempered by an LDM chemotherapy regimen.

RESULTS

MTD chemotherapy renders CAFs pro-oncogenic

To study the effect of chemotherapy on the interactions between CAFs and their cognate cancer cells in an experimentally controlled manner, we developed a protocol to simultaneously isolate tumor fibroblasts and carcinoma cells from the same freshly excised primary tumors from patients with breast cancer using sequential enzymatic digestion and cell sorting (Fig. 1 A). From a cohort of 15 patients who did not receive preoperative chemotherapy (Table S1), we successfully isolated three pairs of CAFs and carcinoma cells that each could be propagated for at least 15 passages and thereby permitted extensive in vitro and in vivo analysis. After verifying the epithelial origin of the breast carcinoma cells using the marker pan-cytokeratin and the CAFs using the markers CD90 and α-smooth muscle actin (α-SMA; not depicted), we selected two paired cell sets, BCAF-011 (isolated from the tumor of a patient with estrogen receptor [ER]–, progesterone receptor [PR]–, and HER2-negative breast cancer) and BCAF-008 (isolated from a patient with ER-positive, PR-positive, and HER2-negative breast cancer) and their cognate breast epithelial cancer cells BC-011 and BC-008, for further analysis. Both sets of minimally passaged CAFs (less than three passages) were treated with nanomolar concentrations of three standard chemotherapeutic agents, doxorubicin, paclitaxel, or 4-hydroxy-cyclophosphamide (4H-CPA; the...
active metabolite of cyclophosphamide), routinely used to treat human breast cancers, and the cells were exposed over time interval and at a dosage that best approximated the mean serum levels achieved in patients, as estimated by pharmacodynamic studies using a standard clinical MTD regimen (50 nM × 96 h, 650 nM × 24 h, and 150 nM × 1 h, respectively; Fig. 1 B; Struck et al., 1987; Twelves et al., 1991; Fogli et al., 2002). Serial monitoring of the treated CAFs revealed early onset (between 3 and 14 d after initiation of the treatments) apoptosis in a population (10–20%) of fibroblasts, whereas the bulk of the treated cells survived that treatment (4 wk) and were found to be growth arrested and express features of senescence and mitotic dysregulations (Fig. 1 C and not depicted).

To explore whether the MTD chemotherapy–treated CAFs (MTD-CAFs) may modulate the behaviors of the neighboring carcinoma cells, we co-cultured the surviving CAFs collected at 2 wk after initiation of the treatments with their cognate carcinoma cells in a three-dimensional (3D) culture assay that recapitulates the tissue-like architecture of breast tumor tissue (Tsai et al., 2005). Notably, when compared with the vehicle-treated CAFs, all pairs of the MTD-doxorubicin−, MTD-paclitaxel−, or MTD–4H–CPA–treated BCAF-011 CAFs substantially enhanced the growth and promoted the invasive behavior of their cognate carcinoma cells (Fig. 1, D–F). The stimulatory effects of MTD chemotherapy on cancer cells were consistently observed in other paired BC-008 carcinoma cells and BCAF-008 CAFs and are unlikely to be cancer subtype–specific, as MTD-CAFs also promoted the invasive growth of established breast carcinoma cells, including the basal subtype HCC-1954 cells and the luminal subtype MCF-7 cells (Fig. 1 E).

To examine whether the MTD–treated CAFs could also promote tumor progression and aggression in vivo, we lentivirally transduced the primary BC-011 carcinoma cells with firefly luciferase (FFLuc) and orthotopically inoculated them with vehicle- or MTD-doxorubicin–treated BCAF-011 CAFs at a cancer cell to CAF ratio of 1:2 into the mammary fat pads of immunodeficient NOD/Shi-scid/IL2Rγnull (NOG) mice (Fig. 1 G), with the tumors generated by this model recapitulating the histological features, especially the CAF contents (~40–45%), of the primary human breast cancer they were excised from (Fig. 1 H). In line with the preceding in vitro findings, those tumor cells co-injected with MTD-CAFs grew significantly faster and developed lymph node and pulmonary metastasis at both a higher frequency and with a shorter latency than the tumor cells injected with vehicle–treated CAFs (Fig. 1 I). These findings indicate that MTD chemotherapy endows CAFs with the ability to foster tumor growth and aggression.

MTD–CAFs expand the population of TICs

Our ensuing functional studies revealed that MTD-CAFs not only promoted the invasive growth of the co-cultivated breast carcinoma cells, but also rendered them significantly more refractory to chemotherapy (Fig. 2 A). These observations raised the possibility that the MTD-CAFs may have fostered the expansion of TICs, defined as cells with tumor-initiating and treatment-resistant properties, within the co-injected population of carcinoma cells (Visvader and Lindeman, 2008). To address this possibility, we co-cultivated carcinoma cells with vehicle- or MTD–chemotherapy–treated CAFs within a dual chamber co-culture apparatus. As implied by our in vivo study results, we found that BC-011 carcinoma cells when cultured together with MTD-CAFs, regardless of their inducing agents, contained a higher percentage of CD44+CD24low− cells, and we determined that this population of cells increased progressively over time (Fig. 2 B and Fig. S1; Al-Hajj et al., 2003; Liu et al., 2014). MTD-CAFs also raised the percentage of CD44+CD24low− cells in several established breast cancer cell lines (Fig. 2 C). These CD44+CD24low− carcinoma cells up-regulated mesenchymal cell markers and were highly invasive and had enhanced tumor-initiating potentials both in vitro and in vivo (not depicted). Consistently, breast carcinoma cells co-cultivated with MTD-CAFs exhibited higher tumorsphere-forming abilities in a limiting dilution assay (Fig. 2, E and F). Interestingly, MTD-CAFs also significantly increased the population of cells with high aldehyde dehydrogenase (ALDH) activity (ALDHhigh), which is known to contain another enriched population of TICs (Ginestier et al., 2007), in luminal subtype BT-474 carcinoma cells (Fig. 2 D), albeit to a lesser extent than the increase in the percentage of CD44+CD24low− cells. Intriguingly, further meticulous cell subpopulation experiments revealed that the CD44+CD24low− TICs were not derived from the ALDHhigh cells but were mainly derived from those carcinoma cells that were neither CD44+CD24low− nor with high ALDH activity (i.e., non-CD44+CD24low−/ALDHlow cells, representing more differentiated carcinoma cells) when they were co-cultivated with MTD-CAFs (Fig. 2, G and H). These data suggest that these TICs were likely derived through the dedifferentiation or the reprogramming of differentiated carcinoma cells (Vermeulen et al., 2010; Lliopoulos et al., 2011; Liu et al., 2014; Zhang et al., 2015).

To explore the in vivo significance of the expansion of TICs induced by MTD-CAFs, we lentivirally transduced BC-011 cells with GFP and inoculated them together with vehicle– or MTD–treated CAFs into the mammary fat pads of NOG mice and assessed levels and expansion of TICs within the resultant tumors (Fig. 2 I). Consistent with the notion that MTD-CAFs stimulate the conversion of TICs from within a breast tumor population, we observed that the percentage of GFP+CD44+CD24low− carcinoma cells substantially increased in those tumors co-injected with MTD– and not vehicle-treated CAFs (Fig. 2 J). These data argue that MTD-CAFs can stimulate the conversion of and support the expansion of TICs within a population of breast carcinoma cells.
Figure 1. MTD chemotherapy–treated CAFs are pro-oncogenic. (A) Schematic illustrating strategy used to prepare primary CAFs or carcinoma cells from fresh human breast cancer for subsequent treatments and analyses. MACS, magnetic-assisted cell sorting. (B) Schematic showing doxorubicin, paclitaxel, or 4H-CPA treatment protocols that mimic MTD chemotherapy regimens in the clinical settings. Arrows indicate time of drug clearance by wash; arrowheads indicate time of analysis (14 d after initiation of the treatments). (C) PKH2-labeled BCAF-011 CAFs were treated with doxorubicin as in B, and the cells were fixed and stained with cleaved caspase-3 (representing apoptotic cells) or senescence-associated β-gal (SA-β-gal; representing senescent cells) at the indicated time after initiation of treatments. Data from two independent experiments (n = 3 in each group; mean ± SEM) are shown. (D) Representative immunofluorescence images of BC-011 carcinoma cells lentivirally transduced with monomeric red fluorescence protein (mRFP; red) co-cultivated in 3D multicomponent gels with vehicle-, MTD-doxorubicin–, MTD-paclitaxel–, or MTD–4H-CPA–treated BCAF-011 CAFs (PKH2 labeled; green). Bars, 200 µm. (E) Bar graphs quantifying the number of breast carcinoma cells per image field after 7 d of co-culture with vehicle- or chemo-treated BCAF-011 or BCAF-008 CAFs. Data from three independent experiments (n = 3 in each group) are shown. (F) The invasive capacities of BC-011 carcinoma cells in response to vehicle- or MTD-CAFs in a Transwell invasion assay. (Top) Shown are representative immunofluorescence images of the invaded cells, with cell nuclei stained with CYTOX-green dye. Bars, 100 µm. (Bottom) The numbers of invaded cancer cells. Data from three independent experiments (n = 3 in each group) are shown. (G) BCAF-011 CAFs were treated with MTD-doxorubicin (MTD-CAF) or vehicle (Vehicle-CAF) and then co-injected with FFLuc-transduced BC-011 carcinoma cells into the mammary fat pads of immunodeficient NOG mice. Tumor bulk was monitored using bioluminescence imaging (BLI). (H, left) Representative immunohistochemical images of α-SMA staining in a desmoplastic tumor generated by co-inoculating primary BC-011 breast cancer cells and BCAF-011 CAFs into the mammary fat pads of NOG mice (TMH-BC-011 tumor; top) and the parental human breast cancer tissue (TMH-BC-011 tumor; bottom). Bar, 100 µm. (Right) Percent α-SMA–positive cells in the microscopic field. At least 10 different areas were examined in each tissue. Data from three independent experiments are shown. (I, left) Representative BLI of tumors at the indicated time after cell inoculation as described in G. (Right) Tumor bulk quantified as BLI normalized photon counts as a function of time. Data from one experiment (n = 6 in each group) are shown. Data are mean ± SEM; Student's t test. **, P < 0.01; ***, P < 0.001.
MTD–CAFs produce elevated levels of ELR+ chemokines

To elucidate the mechanism whereby MTD–CAFs might promote the conversion and expansion of mesenchymal-like TICs, we conducted serial transcriptomic analysis on MTD-doxorubicin– and MTD-paclitaxel–treated CAFs. Not surprisingly, we found that the pattern of gene expres-
sion changed dramatically between vehicle- and MTD-treated CAFs, and we noted that these effects became more pronounced over time (Fig. 3 A). Functional clustering analysis of a group of 2,046 differentially expressed genes (DEGs) detected in vehicle (Veh)-, MTD-doxorubicin–, or MTD-paclitaxel–treated BCAF-011 CAFs. The map depicts high (yellow) and low (blue) relative levels of medium-centered gene expression in log space (n = 2 at each time point). (B) Network map of enriched functional gene categories in the 2,046 late-response genes (i.e., differentially expressed genes at day 7 and/or day 14 after initiation of the treatment) detected in the chemotherapy-treated CAFs. GO-BP, gene ontology biological process; GO-CC, gene ontology cellular component; SPK, SwissProt keywords. (C) Relative transcript levels of the ELR + chemokines CXCL1, CXCL2, CXCL5, and CXCL6 in vehicle-, MTD-doxorubicin–, or MTD-paclitaxel–treated CAFs. Data from two independent experiments (n = 3 in each group; ***, P < 0.001) are shown. (D) The amounts of the secreted ELR + chemokines detected in the conditioned medium from vehicle- and MTD-doxorubicin– or MTD-paclitaxel–treated CAFs. Data from two independent experiments (n = 3 in each group; *, P < 0.05; ***, P < 0.001) are shown. ND, not detected. (E) HistoGene-stained breast cancer tissue sections before (left) and after (right) LCM. The microdissected samples (top right) containing mainly (95%) stromal fibroblasts (yellow arrows), and those containing cancer cells were collected from the same tissue sections for subsequent RNA isolation. White arrows indicate carcinoma cells. Bars, 50 µm. (F) Relative transcript levels of the ELR + chemokines measured in laser-captured tissue excised from the CAF-enriched tumor stroma (left) or the adjacent carcinoma cell–enriched region of neoadjuvant-treated or untreated human breast cancer tissues (right). At least six dissections were performed from different tumor areas from each sample. Data from three independent pairs of tumor samples (**, P < 0.001 vs. untreated tumors) are shown. Data are mean ± SEM; Student’s t test.
The clinical relevance of the MTD-induced CAF phenotype was then verified in CAFs and epithelial tumor cells isolated by laser-capture microdissection (LCM) from neoadjuvant MTD chemotherapy–treated compared with untreated human breast cancer tissue (n = 6 for each; Fig. 3 E). In comparison with untreated tumors, the expression of each of the identified ELR+ chemokines in the CAFs in the neoadjuvant-treated tumor tissue was significantly higher (Fig. 3 F, left). In contrast, there was no quantifiable difference in the expression of any of these chemokines in the epithelial tissue compartment (Fig. 3 F, right). These findings reveal that systemic MTD chemotherapy induces tissue CAFs to produce a unique profile of chemokines.

**MTD–CAFs promote tumor neovascularization and macrophage infiltration and expand TICs through the ELR+ chemokine–CXCR–2 signaling axis**

Tumors with elevated levels of ELR+ chemokines are more aggressive, and this phenotype has been attributed to their ability to stimulate angiogenesis or promote macrophage–induced immune suppression within tumors (Ali and Lazennec, 2007; Seifert et al., 2016). In addition, ELR+ chemokines can also foster the growth and survival of stem cells (Liu et al., 2011; Jung et al., 2015). Consistently, both an in vitro angiogenesis assay and a tumor neovascularization assay revealed that the MTD–CAFs markedly promoted endothelial tube formation and tumor neovascularization, which could be efficiently blocked by SB225002, a specific inhibitor of the conserved ELR+ chemokine receptor CXCR–2 (Fig. 4, A and B). Given the abundance of data linking chemotherapy with the infiltration of tumor-promoting TAMs (Shree et al., 2011; Bruchard et al., 2013; Hughes et al., 2015), we also considered the possibility that the recruitment of myeloid cells to tumors by chemotherapy is at least partially mediated through CAFs. Consistently, MTD–CAFs enhanced the invasiveness of macrophages in a CXCR–2–dependent manner (Fig. 4 C), and the tumors generated by co-inoculating MTD–CAFs and carcinoma cells consisted of more tumor-infiltrating TAMs, as indicated by their specific markers F4/80 and Fizz–1, than those in vehicle–CAF–containing tumors (Fig. 4 D). Importantly, in line with the prometastasis functions of ELR+ chemokines (Liu et al., 2011; Jung et al., 2015), treatment with the CXCR–2 inhibitor also reduced the level of CD44+CD24low/– TICs within the breast carcinoma cells co-cultured with MTD–CAFs (Fig. 4 E). Indeed, each of the ELR+ chemokines individually, but most especially CXCL–1 and CXCL–5, was able to significantly enhance the tumor-sphere-forming ability and enhance the invasive behavior of the CD44+CD24low/– TICs (Fig. 4, F and G), and each of these phenotypes could be significantly inhibited by treatment with SB225002 and/or a neutralizing antibody directed against individual chemokines (Fig. 4, H and J). These findings imply that the ELR+ chemokines secreted by MTD–CAFs exert pleiotropic tumor-promoting effects by stimulating angiogenesis and TAM recruitment and by increasing the population of TICs through CXCR–2 activation.

**LDM chemotherapy attenuates ELR+ chemokine induction in CAFs**

We next sought to exploit alternative therapy regimens that could be adopted to temper the stroma response without the need for additional therapeutic intervention. In this regard, tumors treated using LDM therapy show enhanced tumor treatment response that has been attributed to reduced angiogenesis and immune modulation (Kerbel and Kamen, 2004; Lutsiak et al., 2005; Ghiringhelli et al., 2007; Tanaka et al., 2009). Given our striking findings showing that MTD–CAFs secrete enormous amounts of ELR+ chemokines that induce angiogenesis and TAM infiltration and expand TICs, we explored the possibility that the enhanced therapy response observed after LDM therapy might be caused by a tempered CAF/ELR+ chemokine phenotype. To test this possibility, we designed a LDM-mimetic treatment regimen in which CAFs were treated with low–dose doxorubicin (20 nM) daily for 10 consecutive days (LDM–doxorubicin) to yield an accumulative dose of the drug that was comparable with that used in the MTD regimen (Fig. 5 A). Remarkably, we observed that LDM-treated CAFs (LDM–CAFs) expressed significantly lower levels of the ELR+ chemokines (Fig. 5 B). Similarly, paclitaxel or 4H–CPA administered to CAFs according to the LDM-mimetic regimen also failed to induce ELR+ chemokine expression to the level observed in CAFs subjected to the same drugs using an MTD regimen (Fig. 5, C–F).

To clarify the origins for the differential ELR+ chemokine response elicited in the CAFs, we exposed CAFs to the same total amount of doxorubicin over a protracted period of time using the different dosing regimens (Fig. 5 G). Surprisingly, we observed that when doxorubicin was administered at daily divided doses extending beyond 6 d (regimen LDM–R2), doxorubicin treatment failed to stimulate ELR+ chemokine expression in the CAFs (Fig. 5 H), implying the blunted ELR+ chemokine induction reflects the dosing schedule. To further explore the possibility that the LDM schedule reduced ELR+ chemokine production by the CAFs, we lentivirally transduced BCAF–011 CAFs with GFP and inoculated them together with BC–011 carcinoma cells into the mammary fat pad of NOG mice. Once the tumors were established (2 wk after cell inoculation), we then subjected the mice to a clinically relevant MTD regimen (Fig. 5, C–F).
Figure 4. The pleiotropic effects of MTD chemotherapy–treated CAFs mediated through the ELR+ chemokine–CXCR-2 paracrine signaling axis. (A) Bar graphs showing the increased endothelial tube formation induced by MTD-doxorubicin– or MTD-paclitaxel–treated BCAF-011 CAFs that could be reduced by treatment with the CXCR-2 inhibitor SB225002 (1 µM) or prevented when LDM-mimetic regimens as described in Fig. 5 (A and C) were used to treat CAFs. Data from two independent experiments (n = 3 in each group) are shown. (B, left) Representative photomicrographs showing pronounced vascularity in tumors formed by orthotopically implanted BC-011 carcinoma cells along with MTD-doxorubicin (MTD-CAF)– or vehicle (vehicle-CAF)–treated CAFs with or without concurrent intraperitoneal injections of SB225002 (0.5 mg/kg/day) in NOG mice. Also shown are immunohistochemical images of von Willebrand factor (vWF) staining of the endothelial cells in the tumors. Bar, 50 µm. (Right) Quantification of microvessel density (MVD) per high-power field (HPF) in tumors. At least 10 different areas were examined in each tissue. Data from one experiment (n = 3 in each group) are shown. (C, left) The invasive capacities of U937-derived macrophages in response to vehicle-CAFs, MTD-CAFs, or LDM-CAFs in the absence or presence of 1 µM SB225002 in a Transwell invasion assay. Shown are representative immunofluorescence images of the invaded cells, with cell nuclei stained with CYTOX-green. Bar, 100 µm. (Right) The numbers of invaded macrophages. Data from two independent experiments (n = 3 in each group) are shown. (D, left) Representative immunohistochemical images of F4/80 staining in tumors formed by subcutaneous inoculation of BC-011 cells along with vehicle–, MTD–, or LDM–CAFs in the flank of nude mice. Bar, 50 µm. (Right) Percent F4/80– or Fizz-1–positive cells in the microscopic field. At least 10 different areas were examined in each tissue. Data from two independent experiments (n = 3 tumor tissues in each group) are shown. (E) BCAF-011 CAFs were treated with vehicle– (vehicle-CAF), MTD– (MTD-CAF), or LDM-doxorubicin or paclitaxel (LDM-CAF) as in Fig. 5 and then co-cultivated with BC-011 carcinoma cells in the presence or absence of 1 µM SB225002 in a dual chamber culture apparatus for 5 d, after which the carcinoma cells were subject to flow cytometric analyses. Shown are the percentages of the CD44+CD24low carcinoma cells. Data from two independent experiments (n = 3 in each group) are shown. (F) Freshly sorted CD44+CD24low BC-011 carcinoma cells were cultured in the presence of human recombinant CXCL-1, -2, -5, and -6 (each at 1 µg/ml) or vehicle in low-attachment culture plates for 10 d, and the diameters of the tumorspheres generated were quantified. Data from two independent experiments (n = 3 in each group) are shown. (G) The ability of CD44+CD24low BC-011 carcinoma cells to invade through reconstituted basement membrane in response to human recombinant CXCL-1, -2, -5, and -6 (each at 1 µg/ml) in a Transwell invasion assay. Data from two independent experiments (n = 3 in each group) are shown. (H) The percentages of CD44+CD24low cells in BC-011 carcinoma cells co-cultivated with vehicle– or MTD–CAFs along with the neutralizing antibody directed against individual
this effect can be significantly blunted when an LDM treatment regimen is applied.

LDM chemotherapy prevents therapy-induced expansion of TICs

We next assessed the functional consequence of the LDM chemotherapy on the tumor phenotype. Importantly, in vitro co-culture and animal studies revealed that, as compared with the MTD-CAFs, the ability of the LDM-CAFs to promote tumor neovascularization (Fig. 4, A and B), the invasiveness of macrophages, and the tumor infiltration of TAMs (Fig. 4, C and D), to expand the population of CD44+CD24low−/− TICs (Fig. 4 E), to increase the frequencies of tumortosphere formation (Fig. 4 I), and to promote the invasive phenotype (Fig. 4 J) was greatly blunted. Moreover, FACS analysis of the GFP-transduced carcinoma cells co-inoculated with CAFs into the mammary fat pads of NOG mice, which were subjected to either an MTD- or an LDM-doxorubicin regimen by intraperitoneal injection (Fig. 5 K), revealed that the percentage of CD44+CD24low−/− TICs increased substantially in the tumors from MTD-doxorubicin–treated mice but did not in the LDM-doxorubicin–treated mice (Fig. 5 L). These findings argue that the improved patient response observed after an LDM-chemotherapy treatment regimen likely reflects a tempering of CAF activation characterized by reduced ELR+ chemokine induction and a consequent reduction in TIC expansion and tumor aggression.

LDM chemotherapy attenuates therapy-triggered STAT−1/NF-κB−ELR+ chemokine signaling in CAFs

To clarify why MTD treatment induces such a profound stromal fibroblast activation, we conducted bioinformatics knowledge-based analysis on the promoters of the up-regulated ELR+ chemokines. Our experiments revealed that each of these chemokine promoters harbored an enrichment for STAT-1 and nuclear factor κ light-chain enhancer of activated B cells (NF-κB) binding motifs (Fig. 6 A). In line with this prediction, immunoblot analysis revealed that only MTD-treated but not LDM-treated CAFs had elevated levels of phosphorylated STAT-1 (p−STAT-1) as well as an increased ratio between the phosphorylated form and the total abundance of the NF-κB inhibitor protein IκBα (l-IκBα; Fig. 6, B and C), and luciferase reporter assays revealed heightened STAT-1 and NF-κB transcriptional activities in MTD-treated CAFs but much less in LDM-treated CAFs (Fig. 6 D). Consistently, immunohistochemical analyses confirmed that the p−STAT-1−positive, activated CAFs were abundantly present in the stroma of MTD-doxorubicin–treated tumors but much less so in LDM-therapy–treated tumors (Fig. 6 E). A functional link between elevated STAT-1 and NF-κB activity and ELR+ chemokine production in the MTD-CAFs was further demonstrated by showing that BCAF-011 CAFs lentivirally transduced with a phosphorylation-deficient mutant of STAT-1 or IκBα were unable to up-regulate expression of any of the ELR+ chemokines after MTD treatment (Fig. 6 F). Moreover, loss of STAT-1 and NF-κB activity in the MTD-CAFs inhibited their ability to expand the population of CD44+CD24low−/− TICs within the parental breast cancer cell population (Fig. 6 G). These data suggest that MTD chemotherapy treatment activates STAT-1 and NF-κB in CAFs, which thereafter induces ELR+ chemokine expression that, once secreted, fosters the transdifferentiation and expansion of TICs. This phenotype is prevented using a LDM treatment regimen and, consequently, so too is the enrichment for TICs.

LDM chemotherapy enhances treatment response in desmoplastic breast cancer

Given our finding that LDM chemotherapy tempers CAF activation and TIC expansion, we next asked whether an LDM regimen would reduce tumor aggression and enhance treatment response. To begin with, we noted that the orthotopic tumors developed in mice co-injected with BC-011 carcinoma cells, and LDM-CAFs not only grew considerably slower than the tumor cells co-inoculated with MTD-CAFs, but we also detected fewer lymph nodes and distant metastatic tumors (Fig. 7 A and not depicted). To determine whether these phenotypes could be replicated after in vivo chemotherapy, we first confirmed that the clinically relevant MTD- and LDM-mimetic doxorubicin therapy (Fig. 5 A) both were able to efficiently kill most (>90%) of the carcinoma cells in vitro (Fig. 7 B), based on which we devised MTD- and LDM-mimetic chemotherapy regimens that mimicked the cyclic systemic treatment of breast cancer patients (Fig. 7 C). We first sought to directly investigate the effect of systemic chemotherapy–treated CAFs on tumor cells by stably infecting HCC-1954 carcinoma cells (derived from a patient with a basal-subtype primary breast cancer) with the antiapoptotic protein Bcl-2, which rendered them apoptotic and treatment resistant (not depicted), and co-inoculated them with BC-011 CAFs into the flanks of nude mice. The mice then received cyclic injections of either vehicle or doxorubicin using either the MTD- or the LDM-mimetic regimen. Consistent with our earlier findings, we noted that the chemo-resistant BCL-2−expressing tumors in the mice treated with the MTD

ELR+ chemokines. Data from two independent experiments (n = 3 in each group) are shown. (I) Limiting dilution assay demonstrating the tumortosphere formation efficiency of BC-011 carcinoma cells cultured in the conditioned medium from MTD- or LDM-CAFs. The arrow indicates change of slope of the trend line, suggestive of differential tumortosphere formation ability. Data from one experiment (n = 6 in each group; mean ± SEM; Student’s t test; ***, P < 0.001 vs. MTD) are shown. (J) The invasive capacities of BC-011 cells in response to vehicle−, MTD−, or LDM-CAFs, with or without 1 μM SB225002, in a Transwell invasion assay. Shown are the numbers of the invaded cancer cells per microscopic field. Data from two independent experiments (n = 3 in each group) are shown. (A−H and J) Data are mean ± SEM; Student’s t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus vehicle. †, P < 0.05 versus MTD.
Figure 5. LDM chemotherapy attenuates the treatment-induced expressions of ELR+ chemokines in CAFs. (A) Schematic showing doxorubicin treatment protocols that mimic MTD and LDM chemotherapy regimens. (B) The transcript levels of the ELR+ chemokines CXCL1, CXCL2, CXCL5, and CXCL6 in vehicle, MTD-doxorubicin-, or LDM-doxorubicin–treated BCAFs-011 or BC-008 CAFs 14 d after initiation of the treatments. Data from two independent experiments (n = 3 in each group) are shown. (C) Schematic showing paclitaxel treatment protocols that mimic MTD (650 nM × 24 h) and LDM (65 nM daily × 10 d) chemotherapy regimens (n = 3 in each group). (D) The transcript levels of the ELR+ chemokines in vehicle-, MTD-paclitaxel–, or LDM-paclitaxel–treated BCAFs-011 CAFs 14 d after initiation of the treatments. Data from three independent experiments (n = 3 in each group) are shown. (E) Schematic showing 4H-CPA treatment protocols that mimic MTD (150 nM × 1 h) and LDM (15 nM × 1 h daily for 10 d) chemotherapy regimens. (F) The transcript levels of the ELR+ chemokines in vehicle, MTD–4H-CPA–, or LDM–4H-CPA–treated BCAFs-011 CAFs 14 d after initiation of the treatments. Data from three independent experiments (n = 3 in each group) are shown. (G) Schematic showing doxorubicin treatment protocols that recapitulate MTD (50 nM × 96 h)- or different LDM-mimetic regimens with gradually prolonged lengths of drug exposure (from LDM-R1 to LDM-R4). Note that the total accumulated doses of drug exposure, as reflected in area under curves, were the same across all the treatment groups (4,800 nM × h). (A, C, E, and G) Arrows indicate time of drug clearance by wash. (H) Fold-increases in the transcript levels of the ELR+ chemokines in BCAFs-011 CAFs exposed to vehicle or doxorubicin using the treatment protocols described in G. Data from three independent experiments (n = 3 in each group) are shown. (I) BCAFs-011 CAFs were lentivirally infected with GFP and then co-injected with BC-011 carcinoma cells into the mammary fat pads of NOG mice. 2 wk after cell inoculation, the tumors were given injections of vehicle or doxorubicin at an MTD (2 mg/kg as a single-dose intravenous injection)– or an LDM (0.2 mg/kg every day by intraperitoneal injections for 10 consecutive days)–mimetic therapy regimen and then removed for cell dissociation followed by transcript analyses. (J) The transcript levels of the ELR+ chemokines in the GFP+ CAFs isolated from the tumors described in I. Data from one experiment (n = 5 in each group) are shown. (K) BCAFs-011 CAFs were co-inoculated with GFP-transduced BC-011 carcinoma cells into the mammary fat pads of NOG mice. The resultant tumors were given injections of vehicle or doxorubicin at a MTD- or a LDM-mimetic regimen as described in I. The tumors were then removed for cell dissociation followed by flow cytometric analyses. (L) The percentages of GFP+CD44+CD24−low cells relative to the GFP+ carcinoma cells isolated from the tumors described in K. Data from one experiment (n = 5 in each group) are shown. Data are mean ± SEM; Student’s t test. *, P < 0.05; **, P < 0.01 versus vehicle. †, P < 0.05 versus MTD.
chemotherapy protocol grew significantly faster than either the vehicle-treated mice or the mice subjected to a LDM therapy regimen (Fig. 7D). In a second model wherein the mammary fat pads of NOG mice were co-inoculated with control and apoptotic-sensitive HCC-1954 cells and primary CAFs, single-agent therapy with LDM-doxorubicin could profoundly inhibit the growth of the tumors, and its treatment efficacy was comparable with that in those con-
Figure 7. LDM chemotherapy enhances treatment response and prevents TIC expansion in desmoplastic breast cancer. (A, left) BCAF-011 CAFs were treated with MTD (MTD-CAF) or LDM-doxorubicin (LDM-CAF) as in Fig. 5A and then co-injected with FFLuc-transduced BC-011 carcinoma cells into the mammary fat pads of NOG mice. Tumor bulk was then monitored using BLI. Shown is representative BLI of tumors at the indicated time after cell inoculation. (Right) Tumor bulk quantified as BLI normalized photon counts as a function of time. Data from one experiment (n = 6 in each group; mean ± SEM; Student’s t test; *, P < 0.05; ***, P < 0.001 vs. MTD-CAF) are shown. (B) HCC-1954 carcinoma cells were treated with vehicle or doxorubicin using an MTD- or an LDM-mimetic regimen as described in Fig. 5A, and the cells surviving the therapy were determined by CTOX-orange/Hoechst 33342 two-color fluorescence cell viability assay 10 d after initiation of the treatments. Data from three independent experiments (n = 3 in each group) are shown. (C) Schematic showing in vivo doxorubicin treatment protocols that mimic MTD and LDM chemotherapy regimens. The tumor-bearing mice received cyclic (three cycles) injections of vehicle or doxorubicin using an MTD (2 mg/kg by intravenous injections every 10 d for three cycles)- or an LDM (0.2 mg/kg by intraperitoneal injections daily for 30 d)-mimetic regimen. (D) BCAF-011 CAFs were co-inoculated with Bcl-2–transduced HCC-1954 carcinoma cells subcutaneously into the flanks of nude mice. 2 wk later, the tumor-bearing mice received cyclic intraperitoneal injections of vehicle or doxorubicin using the MTD- or LDM-mimetic regimen as described in C. (Left) Shown are representative bioluminescence images of tumors at the indicated time after initiation of the therapy. (Right) Tumor bulk quantified as BLI normalized photon counts as a function of time. Data from one experiment (n = 6 in each group) are shown. (E) BCAF-011 CAFs were co-inoculated with FFLuc-transduced HCC-1954 carcinoma cells into the mammary fat pads of NOG mice, and the resultant tumors were treated as in C with or without concurrent intraperitoneal injections of SB225002 (0.5 mg/kg/day) in the mice. (Right) Tumor bulk plotted over time. Data from one experiment (n = 6 in each group) are shown. (F) FFLuc-transduced HCC-1954 carcinoma cells were inoculated into the mammary fat pads of NOG mice without co-inoculation of CAFs. The resultant pauci-CAF tumors were treated as in C, and the tumor bulk was plotted over time. Data
currently treated with MTD therapy and the CXCR-2 inhibitor (Fig. 7 E). Notably, the desmoplastic tumors treated with the MTD-mimetic regimen outgrew the control tumors during the initial period of the treatment (day 0 to day 31 in Fig. 7 E), whereas the same MTD therapy significantly suppressed the growth of the tumors generated when only the carcinoma cells without CAFs were inoculated into the mice despite that these pauci–CAF tumors grew much more slowly than the desmoplastic tumors (Fig. 7 F). This result raised the intriguing possibility that the tumor-promoting effects of the chemo–treated CAFs may override the cytotoxic and antitumor effect of traditional MTD chemotherapy in certain stroma cell–abundant desmoplastic tumors. We also verified that the higher antitumor efficacy of LDM therapy than MTD therapy was not drug specific, as it was also evident when the cancer cell/CAF co-culture was treated with other types of chemotherapy agents such as paclitaxel and 4H–CPA (Fig. 7 G).

To validate that LDM therapy indeed imparts therapeutic benefits in a more clinically relevant paradigm, we repeated the in vivo animal studies using highly aggressive breast cancer MDA-MB-436 cells in CD34 hematopoietic stem cell (HSC)–reconstituted humanized NOG (HSC-hu-NOG) mice, which contain functionally differentiated human immune cells. We found that the LDM tumors in this humanized mouse model of orthotopic and desmoplastic breast cancer responded to LDM therapy but not to standard MTD chemotherapy so that the LDM therapy–treated mice survived significantly longer than those subjected to standard chemotherapy (Fig. 8, A and B), supporting that LDM therapy indeed conferred survival benefits to tumor-bearing mice. In addition, flow cytometric analyses of the resulting tumors revealed that the mice treated with standard MTD chemotherapy had a greater number of CD44+CD24low/− TICs as compared with those administered the LDM therapy regimen or co-administered with the CXCR-2 inhibitor (Fig. 8, C and D). Because these phenotypes were not observed in tumors generated in mice orthotopically injected with the carcinoma cells alone (Fig. 8, E and F), these findings support our notion that chemotherapy treatment can drive tumor aggression and treatment resistance by activating stromal fibroblasts. Next, as mouse xenografts of human cancer cells aggression and treatment resistance by activating stromal fibroblasts. Next, as mouse xenografts of human cancer cells(PDAC) or primary SP−1 PDAC cells co-cultured with MTD–PSCs revealed that these cells contained a progressively increasing percentage of CD44+CD133+ cells or CD44+CD24+ cells (Fig. 9, C–F; and Figs. S3 and S4), which we and others have previously shown to contain TICs in PDAC (Li et al., 2007; Wang et al., 2013), whereas the cells co-cultured with LDM–PSCs had a lower percentage of TICs.

In accordance with the findings in breast cancer, parallel studies using FFLuc-transduced PANC-1 PDAC cells co-injected orthotopically into the pancreas with MTD–PSCs in HSC–hu-NOG mice grew dramatically faster than those co-injected with LDM–PSCs. Moreover, the PANC-1 PDAC

**LDM chemotherapy enhances treatment response in desmoplastic PDAC**

Having demonstrated the beneficial effect of LDM chemotherapy in desmoplastic breast cancer, we asked whether this phenomenon was not confined only to breast cancer–CAF interactions, but also could be extended to other types of desmoplastic cancers such as PDAC (Sherman et al., 2014). It has been shown that LDM chemotherapy can attenuate therapy-induced metastasis caused by rebound MDSC mobilization and increased angiogenesis in PDAC (Hasnis et al., 2014). We therefore sought to compare the impact of an LDM versus an MTD chemotherapy routine on PDAC cells–pancreatic stellate cell (PSC; the most abundant fibroblast–like stromal cells in PDAC) interactions. We treated PSCs with either a clinically relevant MTD (20 µM × 30 min; Grunewald et al., 1992) or an LDM-mimetic (2 µM × 30 min for 10 consecutive days; Fig. 9 A) regimen using the standard of care PDAC chemotherapy drug gemcitabine and assayed transcript levels of ELR+ chemokines in the PSCs. Consistent with our findings in breast CAFs, we found that PSCs treated with MTD–gemcitabine (MTD–PSCs) expressed high levels of all four ELR+ chemokines, whereas those subjected to an LDM regimen (LDM–PSCs) expressed much lower levels of those chemokines (Fig. 9 B). Furthermore, FACS analysis of PANC-1 cells or primary SP−1 PDAC cells co-cultured with MTD–PSCs revealed that these cells contained a progressively increasing percentage of CD44+CD133+ cells or CD44+CD24+ cells (Fig. 9, C–F; and Figs. S3 and S4).
Figure 8. LDM chemotherapy enhances treatment response in humanized or PDX mouse breast cancer models. (A, left) BCAF-011 CAFs were co-inoculated with GFP-FFLuc–transduced MDA-MB-436 carcinoma cells into the mammary fat pads of humanized HSC-hu-NOG mice, and the resultant tumors were treated as in Fig. 7 C with or without concurrent intraperitoneal injections of SB225002 (0.5 mg/kg/d) in the mice. (Right) Tumor bulk plotted over time. Data from one experiment (n = 10 in each group) are shown. (B) Percent survival as a function of time in mice described in A. The black bar indicates the duration of treatment. Data from one experiment (n = 10 in each group; the survival curves were compared using log-rank test; LDM vs. MTD) are shown. (C and D) After the first cycle of chemotherapy in A, the tumors were removed for cell dissociation followed by flow cytometric analyses. (D) Shown are the percentages of CD44+CD24−/low cells relative to the GFP+ carcinoma cells. Data from two independent experiments (n = 3 in each group) are shown. (E) MDA-MB-436 carcinoma cells were inoculated into the mammary fat pads of HSC-hu-NOG mice without co-inoculation of CAFs. The resultant pauci-CAF tumors were treated as in A, and the tumor bulk was plotted over time. Data from one experiment (n = 6 in each group) are shown. (F) The percentages of CD44+CD24−/low cells relative to the GFP+ carcinoma cells isolated from the tumors generated in E. Data from two independent experiments (n = 3 in each group) are shown. (G) Representative immunohistochemical images of α-SMA staining in a PDX breast tumor xenograft. Bar, 100 µm. (H) NOD-SCID γ mice bearing PDX breast tumors were treated with systemic MTD- or LDM-doxorubicin as in Fig. 7 C, and the tumor growth was monitored for 31 d after initiation of the treatments. Shown are representative photographs of the tumors in each group at the study end point. (I) Tumor volume in H plotted over time. Data from one experiment (n = 6 in each group) are shown. (J) The PDX tumors as described in I were removed for cell dissociation followed by flow cytometric analyses after the first treatment cycle (i.e., 11 d after initiation of the treatments). (Left) Shown are representative plots showing patterns of
cells co-injected with the MTD-PSCs rapidly and extensively developed liver, peritoneum, and lung metastasis (Fig. 9 G and not depicted). Indeed, whereas a systemic MTD-mimetic regimen of gemcitabine treatment (Fig. 9 H) fostered the growth and dissemination of orthotopically implanted PANC-1 pancreatic tumors co-injected with PSCs, those same mice treated with an LDM-mimetic regimen survived longer, and their tumors regressed significantly (Fig. 9 I and J).

Collectively, these findings argue that a standard of care MTD chemotherapy regimen activates STAT-1 and NF-κB in stromal fibroblasts to induce ELR+ chemokine expression that then drives tumor aggression and treatment resistance, at least in part by stimulating tumor neovascularization and the infiltration of TAMs and by fostering the transdifferentiation of carcinoma cells and the expansion of TICs (Fig. 10 A). Our results also demonstrate that these effects can be largely tempered by adopting an LDM treatment approach and that the phenotype is not confined to one tumor type but is likely universal in nature (Fig. 10 B).

**DISCUSSION**

In this study, we presented compelling evidence demonstrating that MTD chemotherapy used to treat human cancers can exert sustained effects on the tumor stroma that include the induction of an ELR+ chemokine-producing phenotype in CAFs, whereby they can subsequently promote tumor aggression. Our data revealed that ELR+ chemokine-producing CAFs are abundant and readily detected in cancer tissues, even after multiple cycles of therapy. We further determined that MTX chemotherapy induces a population of CXCR-2-dependent TICs through inducing the CAF ELR+ chemokine–cancer cell paracrine signaling process, which can be much tempered by switching to LDM therapy regimens. Thus, our findings emphasize the crucial contribution of the tissue stroma in cancer treatment and imply that LDM chemotherapy may provide a new avenue for preventing stromal activation to further enhance the therapeutic outcome in desmoplastic cancers.

It is increasingly recognized that systemic chemotherapy can activate the tumor stroma to modulate tumor behaviors in human cancers. In human prostate cancer, the genotoxic agent mitoxantrone was able to stimulate Wnt16B secretion by stromal fibroblasts, which then promoted the proliferation and invasion of the associated carcinoma cells (Sun et al., 2012). In human colorectal cancer, chemotherapy led to the enrichment of IL-17A–producing CAFs within the tumor stroma, which in turn promoted the self-renewal of TICs and tumor growth (Lotti et al., 2013). Echoing these findings, our study showed that, after chemotherapy treatment, breast cancer CAFs chronically up-regulate several factors linked to cell-to-cell and/or cell-to-matrix interactions. Our mechanistic studies additionally dissect the functional alterations in chemo-treated CAFs. An unbiased expression profiling, followed by comprehensive bioinformatics analyses and molecular and functional studies, led to the identification of the ELR+ chemokine–CXCR-2 paracrine signaling process, stimulated by chronically elevated STAT-1 and NF-κB transcriptional activity in CAFs, as an essential mechanism underlying the pro-oncogenic and pro-TIC activities of chemo-treated CAFs. Furthermore, and importantly, we demonstrated the clinical significance of this finding by showing that there is a significant induction of the ELR chemokines in the stroma of neoadjuvant chemotherapy-treated human cancer tissues. It is worth noting that the expressions of several previously reported CAF-derived factors, including CXCL12 (SDF-1α), G-CSF, and VEGF-A (Orimo et al., 2005; McAlister and Weinberg, 2014), were not significantly induced by MTD chemotherapy in CAFs (unpublished data). This indicates that the chemotherapy-elicted stroma alterations are mediated by signaling pathways distinct from those functioning in incipient or chemo-naive tumors.

To date, several clinical trials have supported LDM chemotherapy alone or in combination with targeted therapeutics or antiangiogenic drugs as an effective approach in cancer treatment (Pasquier et al., 2010; Loven et al., 2013). For instance, in patients with breast cancer, it has been estimated that LDM therapy yielded an average response rate of 39% and an average overall clinical benefit of 57%. Recently, a large and randomized phase III trial, the CAIRO3 trial, provided a solid support for the clinical benefits of LDM chemotherapy in metastatic colorectal cancer (Kerbel and Grothey, 2015). The efficacy of LDM therapy has been thought to be mainly caused by its antiangiogenic effects (Kerbel and Kamen, 2004), such as direct cytotoxicity to endothelial cells (Bocci et al., 2002), reduced recruitment of endothelial progenitors (Bertolini et al., 2003), and increased expression of the antiangiogenic factor thrombospondin-1 (Bocci et al., 2003). Recent studies suggest that LDM therapy may also mediate its antitumor effect by inhibiting regulatory T cells (Lusiak et al., 2005; Ghiringhelli et al., 2007), by triggering the maturation of tumor-infiltrating dendritic cells (Tanaka et al., 2009), or by disrupting cancer stem cell–promoting vascular niches (Folkins et al., 2007). Nonetheless, our study identified a new and important mechanism underlying the enhanced therapeutic efficacy of LDM therapy in CAF-abundant, desmoplastic cancers, which is mediated through an attenuated STAT-1 and NF-κB activation in CAFs leading to a substantially reduced ELR+ chemokine production, thereby significantly tempering the therapy-triggered stromal pro-oncogenic activity. Of note, previous studies have indi-

CD298, CD44, and CD24 staining of carcinoma cells with the frequency of the boxed CD44+CD24−/low cell population as a percentage of CD298+ cancer cells shown. (Right) The percentages of CD298+CD44+CD24−/low cells relative to the CD298+ carcinoma cells isolated from the tumors. Data from three independent experiments (n = 3 in each group) are shown. FSC, forward scatter. Data are mean ± SEM; Student’s t test, *, P < 0.05 vs. vehicle; †, P < 0.05 vs. MTD.
cated that the antiangiogenic and antitumor effects of LDM chemotherapy are specifically observed in certain chemotherapeutic agents, which does not include doxorubicin (Bocci et al., 2002). Nonetheless, in our CAF–abundant tumor model, which resembles human desmoplastic breast cancer, doxorubicin treatments administered using an LDM-mimetic reg-

Figure 9. LDM chemotherapy enhances treatment response in desmoplastic PDAC. (A) Schematic showing in vitro gemcitabine treatment protocols that mimic MTD (20 µM × 30 min on the first day, followed by a drug-free interval of 9 d) and LDM (2 µM × 30 min daily for 10 consecutive days) chemotherapy regimens. (B) The transcript levels of the ELR+ chemokines in vehicle (vehicle–PSC), MTD (MTD–PSC), or LDM–gemcitabine (LDM–PSC)–treated PSCs. Data from three independent experiments (n = 3 in each group; *, P < 0.05 vs. vehicle–gemcitabine; †, P < 0.05 vs. MTD–gemcitabine) are shown. (C) Vehicle–, MTD–, or LDM–PSCs were co-cultivated with PANC-1 carcinoma cells in a dual-chamber apparatus for 5 d, and the carcinoma cells were subjected to flow cytometric analyses. Shown are representative plots showing patterns of CD44 and CD133 staining of cells at different times in the co-culture, with the frequency of the boxed CD44+CD133+ cell population as a percentage of cancer cells shown. (D) The percentages of CD44+CD133+ carcinoma cells at different times in the co-culture. Data from three independent experiments (n = 3 in each group; *, P < 0.05 vs. vehicle–PSC; †, P < 0.05 vs. MTD–PSC) are shown. (E) The percentages of CD44+CD133+ or CD44+CD24+ carcinoma cells at day 5 in the co-culture. Data from three independent experiments (n = 3 in each group; *, P < 0.05 vs. vehicle–PSC; †, P < 0.05 vs. MTD–PSC) are shown. (F) Vehicle–, MTD–, or LDM–PSCs were co-cultivated with primary SP-1 PDAC cells, and the percentages of CD44+CD133+ TICs were analyzed. Data from three independent experiments (n = 3 in each group; *, P < 0.05 vs. vehicle–PSC; †, P < 0.05 vs. MTD–PSC) are shown. (G) Vehicle–, MTD–, or LDM–PSCs were co-injected with FFLuc-transduced PANC-1 carcinoma cells into the pancreatic tails of NOG mice. Tumor bulk was then monitored using BLI. (Left) Shown is representative BLI of tumors at the indicated time after cell inoculation. (Right) Tumor bulk quantified as BLI normalized photon counts as a function of time. Data from one experiment (n = 3 in each group; *, P < 0.05 vs. vehicle–PSC; †, P < 0.05 vs. MTD–PSC) are shown. (H) PSCs were co-injected with PANC-1 cells into the pancreatic tails of HSC-hu-NOG mice. 10 d later, the tumor-bearing mice received intraperitoneal injections of vehicle or gemcitabine using an MTD (240 mg/kg every 9 d for 18 d followed by a 9-d rest and then another 18-d treatment cycle)– or an LDM (80 mg/kg every 3 d for 18 d followed by a 9-d rest and then another 18-d treatment cycle)–mimetic regimen. (Left) Representative BLI of tumors at the indicated time after initiation of the therapy as described in (H). (Right) Tumor bulk quantified as BLI normalized photon counts as a function of time. Data from one experiment (n = 3 in each group; *, P < 0.05 vs. vehicle–gemcitabine; †, P < 0.05 vs. MTD–gemcitabine) are shown. (B, D–G, and I) Data are mean ± SEM; Student’s t test. (J) Percent survival as a function of time in mice described in (I). The black bar indicates the duration of treatment. Data from one experiment (n = 3 in each group; the survival curves were compared using log-rank test; LDM vs. MTD) are shown.
The beneficial effects of LDM chemotherapy in desmoplastic cancers.

(A) Schematic showing the proposed mechanisms underlying the pro-oncogenic functions of MTD-CAFs that serve to antagonize the antitumor efficacy and lead to tumor recurrence and/or metastasis, whereas chemotherapy at LDM therapy regimens can exempt the stroma from these treatment-elicited stromal-epithelial signaling events. (B) Both MTD and LDM chemotherapy can lead to regression of tumors with few CAFs in their stroma (i.e., pauci-CAF tumor), whereas in CAF-abundant (i.e., desmoplastic) tumors, MTD chemotherapy induces strong and persistent stroma activation, which undermines the treatment response. MTD chemotherapy may paradoxically promote tumor progression in certain contexts depending on the treatment sensitivity of carcinoma cells and the relative abundance of CAFs or other types of stroma cells. LDM chemotherapy can avoid the inadvertent activation of the tumor stroma, whereby it can enhance the treatment response.

In summary, our findings suggest that systemic chemotherapy has a significant impact on the stroma that is associated with human desmoplastic cancers that includes sustained activation of CAFs leading to pro-oncogenic and pro-TIC paracrine signaling activities. We delineated the signaling pathway that mediates this characteristic stromal response to chemotherapy and identified an effective way to attenuate it by using LDM therapy regimens. Our results lend support to the emerging paradigm that maintains that stroma-derived signals contribute to tumor pathology and suggests that LDM therapy or targeting the paracrine signaling mediated by chemotreated CAFs may be a valid approach for improving therapeutic outcome in desmoplastic cancers.

MATERIALS AND METHODS

Human cancer specimens, staining, and cell isolation

Tumor specimens were excised from a cohort of 15 breast cancer patients who had not received prior chemotherapy in the Tung’s Metro–harbor Hospital, Taiwan (the TMH cohort; Table S1). The specimens were processed within 3 h of tumor removal by mechanical dissociation, enzymatic digestion, and differential centrifugation, as described previously (Tsuyada et al., 2012), followed by sequential magnetic-assisted cell sorting using antifibroblast MicroBeads and a magnetic-assisted cell-sorting Dead Cell Removal kit (Miltenyi Biotec). Fibroblasts were plated on collagen-coated tissue culture plates and maintained in DMEM (Invitrogen) supplemented with 15% FBS. Carcinoma cells were cultured in IMDM (Invitrogen) supplemented with glutamine, insulin, transferrin, selenium (all from Lonza), and 20% FBS (Tsuyada et al., 2012). Using this protocol, we were able to isolate three pairs of cognate carcinoma cells and CAFs that could be propagated for >15

Figure 10.
passages to permit subsequent experiments. Carcinoma cells were confirmed to be aneuploid according to karyotyping. All human tissues were collected using protocols approved by the Institutional Review Boards at Tung Taichung Metropolitan Hospital. Primary PDAC SP-1 cells were isolated from the malignant ascites of a patient with metastatic PDAC (a gift from Y.-S. Shan, National Cheng Kung University Hospital, Tainan, Taiwan). HCC-1954, MCF-7, HCC-1806, HCC-38, BT-474, MDA-MB-436, Panc-1, and U-937 cells (all from ATCC) and PSCs (a gift from M. Löh, German Cancer Research Center, Heidelberg, Germany; Jesnowski et al., 2005) were cultured and propagated according to the providers’ recommendations.

**Treatment of CAFs and PSCs**

Minimally passaged (less than three passages) primary breast CAFs were treated with doxorubicin, paclitaxel, or 4H-CPA (all from Sigma–Aldrich) according to the MTD- or the LDM-mimetic scheme described in Fig. 1 B or Fig. 5 (A, C, and E) (Struck et al., 1987; Twelves et al., 1991; Fogli et al., 2002). PSCs were maintained in DMEM supplemented with 10% FBS and treated with gemcitabine (LILY France) according to the dose schemes described in Fig. 9 A. After the completion of treatments, fibroblasts were washed twice with Dulbecco’s PBS, replenished with drug-free culture media, and then allowed to recover for 14 d after initiation of the treatment. Dead cells that had detached from the culture surface were removed and excluded from subsequent experiments.

**Immunoblot analysis**

Immunoblot protein analysis was performed according to standard protocols. Antibodies used included anti–human α-SMA (1A4; Dako), p16 (DCS-50; Abcam), STAT-1 (1/Stat1; BD), phospho–STAT-1 (Tyr701), NF-κB p65 (C22B4), phospho-1kBα (Ser32/36; 5A5; Cell Signaling Technology), anti–1kBα (6A920), and histone 2B (FL-126; Santa Cruz Biotechnology, Inc.).

**Gene expression profiling and clustering analysis**

Total RNA samples were extracted using TRIzol (Invitrogen) and then purified using an RNaseasy mini-kit (QIAGEN). Gene expression analysis was performed on a GeneChip platform (Human Genome U133A 2.0 Plus; Affymetrix) according to the manufacturer’s instructions. The gene expression data were deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible under accession no. GSE23399. Differentially expressed genes were selected using Student’s t test or Tukey’s honestly significant difference test (P < 0.05; fold-change > 2x). The genes were functionally annotated using DAVID, and the enriched functional gene categories identified were further processed and displayed using Cytoscape. Hierarchical clustering of the selected genes was performed using Cluster and TreeView software.

**Quantitative real-time PCR (qRT–PCR) and ELISA analyses**

qRT-PCR analysis was performed on the amplified RNA using the LightCycler FastStart DNA Master plus SYBR Green I kit (Roche) according to the manufacturer’s instructions. Oligonucleotide primers were designed using LightCycler Probe Design software (Roche) or Primer Bank. Transcript expression was quantified by normalizing the gene of interest copy number (per microliter) to absolute levels of an endogenous, stably expressed reference gene, ribosomal protein L13a (RPL13A). ELISA was performed using kits according to the manufacturer’s instructions (R&D Systems).

**3D co-culture assay**

Breast carcinoma cells were co-cultivated with CAFs on top of a multicomponent 3D extracellular matrix hydrogel consisting of growth factor–reduced reconstituted basement membrane (Matrigel) and type I collagen (both from BD) at a 1:1 ratio (Tsai et al., 2005).

**Cell death assay**

Cell death was analyzed by a two-color fluorescence cell viability assay by counting the nuclei of dead cells using CytOx orange dye (Invitrogen) and normalizing dead cells to total cell number estimated by counterstaining nuclei with Hoechst 33342 (Invitrogen). In selected experiments (Fig. 1 C), cells were stained with active caspase-3 (E83-77; Abcam) for the detection of apoptosis.

**In vivo tumor models and analyses**

In the orthotopic mouse models of desmoplastic breast cancer, NHR1-BC-011, HCC-1954, or MDA-MB-436 cells were lentivirally transduced by a GFP and Fluc fusion vector (UBC-EGFP–T2A-Luc; System Biosciences), and GFP-positive cells were enriched by FACS. In the orthotopic breast cancer model, 5 × 10⁵ cells carcinoma cells and 10⁶ CAFs in 100 µl (1:1 Matrigel/cells) were inoculated into the mammary fat pads of female NOG mice or HSC-hu-NOG mice (National Institute of Infectious Diseases and Vaccinology, Taiwan). Successful engraftment of HSCs was validated by determining the titers of human IgM and IgG and accessing human CD45+, CD3+, and CD19 + cells in the peripheral blood at 8–12 wk after HSC engrafting. In selected experiments (Figs. 4 D and 7 D), the cells were inoculated subcutaneously into the flanks of 8-wk-old female nude mice (National Laboratory Animal Center, National Applied Research Laboratories, Taiwan). In the orthotopic mouse model of desmoplastic PDAC, 5 × 10⁵ Fluc-transduced PANC-1 PDAC cells (ATCC) and 10⁶ PSCs were inoculated into the pancreatic tail of NOG mice or HSC-hu-NOG mice. In selective experiments, the mice were given 0.5 mg/kg/day CXCRI-2 inhibitor SB225002 by intraperitoneal injections 2 d before and after chemotherapy treatments. Tumor mass was quantified weekly by bioluminescence (IVIS Imaging System; Caliper Life Sciences) according to the manufacturer’s directions. Protocols for animal care and experimentation were ap-
proved by the Institutional Animal Care and Use Committee of the National Health Research Institutes, Taiwan, and were adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

In the PDX breast tumor model, NOD-SCID γ (NSG) mice bearing PDX breast tumors (TM00999) derived from a triple-negative (ER “PR HER2”) breast tumor were purchased from The Jackson Laboratory. When tumors became palpable, the mice were administered with MTDO or LDM-doxorubicin or vehicle intraarterially according to the protocol described in Fig. 7 C, and the tumors were calipered weekly to monitor growth kinetics. Tumor volumes were calculated using the formula 0.5 × length × (width)². The animals were euthanized 31 d after initiation of the treatments.

LCM
LCM of breast tumor tissues obtained from the TMH cohort (Table S1) was performed as previously described (Finak et al., 2008) with modifications. In brief, three 7-μm sections each were serially cut from snap-frozen tumor tissues, placed onto a polystyrene naphthalate membrane slide, and stained with a HistoGene LCM Staining kit to isolate distinct CAFs or cancer cell–enriched regions, as identified by an expert pathologist (W.-Y. Chen), by using the Veritas automated LCM system (Arcturus Engineering). Approximately 1,500 cells were collected onto the Capture Macro cap, and the RNA sample was extracted using a Picopure RNA Isolation kit. qRT-PCR assay was performed as described.

Transwell invasion assay
Cancer cell– or PMA (5 nM × 72 h)–primed U937 cells (for in vitro macrophage differentiation) were seeded on Transwell inserts (BD) with a thin layer of growth factor–reduced Matrigel (BD) coating with CAFs seeded in the lower compartments of the Transwell. After an incubation period of 12 h, the cells that invaded through the insert membrane were fixed, stained with CYTOX-green (Invitrogen), and counted using a fluorescence microscope.

Immunofluorescent staining and confocal imaging
Immunofluorescent staining of cells grown on culture plastics was performed using standard protocols. Whole–culture immunofluorescence staining of cells grown in 3D co-culture was executed as previously described (Lee et al., 2007). Confocal imaging was performed using a confocal microscope system (Digital Eclipse C1; Nikon).

Immunohistochemical staining
Formalin–fixed, paraffin–embedded human or mouse tumor tissues were processed using standard protocols, stained with anti–α-SMA (for detection of CAFs; α-sm-1; Abcam), anti–F4/80 (for detection of TAMs; Hycult Biotech), anti–Fizz–1 (for detection of M2-subtype TAMs; Abcam), or anti–p–STAT–1 (for detection in CAFs; Cell Signaling Technology) and then detected by using a Dako EnVision kit. All staining was evaluated by an expert pathologist (W.-Y. Chen).

Reporter assay
Lentivirus–mediated expression of the STAT–1 or NF-κB luciferase reporter vector as well as the reporter assay were performed according to the provider’s recommendations (Cignal Lenti Reporter; SABiosciences).

Manipulation of gene expression
Functional inhibition of STAT–1 or NF-κB activity in CAFs was achieved by generating lentiviral expression constructs for a phosphorylation–deficient mutant of STAT–1–super-repressor (STAT–1–SR; STAT–1–SR pLVX–puro–STAT–1–SR), or a phosphorylation–resistant mutant of IkBα (pLVX–puro–IkB α–SR mutant; NFKBIA–SR; Kuperwasser et al., 2004) and infecting them in minimally passed NHR1–BCAF–011 CAFs. pLVX–puro–STAT–1–SR was generated by subcloning eGFP–STAT–1–Y701F (Addgene) into the pLVX–IRESPuro (Takara Bio Inc.), which was followed by a serine for leucine substitution at amino acid 706 (L706S) to impair the phosphorylation, homodimerization, and nuclear translocation of STAT–1 (Dupuis et al., 2001). Lentivirus production and cell infection were performed according to the manufacturer’s protocols (Takara Bio Inc.). The human B cell CLL/lymphoma 2 (Bcl–2) expression construct pHABE–puro–Bcl2 was obtained from Addgene. Amphotropic retrovirus was produced in Phoenix amphi cells (gift from G. Nolan, Stanford University, Stanford, CA) using the packaging vectors pCgp and pVSV–G to boost viral titer.

Flow cytometry and tumorsphere assays
Cancer cells were dissociated, antibody labeled (1–2 µg per 10⁶ cells × 1 h), and resuspended in HBSS/2% FBS as previously described (Al-Hajj et al., 2003; Li et al., 2007). The antibodies used include APC–anti–CD144, PE–anti–CD44, FITC–anti–CD24, Alexa Fluor 647–anti–CD24 (all from BD), APC–anti–CD133 (Miltenyi Biotech), and anti–CD298 (LNH–94; BioLegend). Flow cytometry was done using a FACSCanto II flow cytometer (BD) with the electronic gating set according to cells stained with the corresponding isotype–matched control IgG. In selected experiments, cancer cells were cultured in the presence of 1 µM SB225002 (EMD Millipore) or a neutralizing antibody directed against 10 µg/ml CXCL–1 (clone 20326; R&D Systems), 10 µg/ml CXCL–2 (Abcam), 10 µg/ml CXCL–5 (R&D Systems), or 10 µg/ml CXCL–6 (clone 60910; R&D Systems) before the flow cytometry analysis. The ALDEFluor assay (STEMCELL Technologies) was performed according to the manufacturer’s recommendation.

To assess the tumorsphere formation efficiency of TICs, CD44⁺CD24⁻⁷⁻ cells and CD133⁺CD44⁺ cells were FACS sorted from breast cancer cells and PDAC cells, respectively, using a FACSaria III cell sorter (BD). The tumorsphere assay for breast TICs was performed using the MammoCult Human
Medium kit (STEMCELL Technologies). The tumorsphere assay for pancreatic TICs was performed as previously described (Arensman et al., 2014). For limiting dilution assay, CD44^CD24^low/− cells were plated in limiting dilution (200, 100, and 50 cells per well) in 96-well plates in the respective culture media. The presence of spheres was evaluated after 5 d.

Statistical analysis
The statistical programming language R and SPSS 10.0 software were used to conduct the statistical analysis of our data. A two-tailed Student’s t test was used for simple significance testing. Survival curves were generated using the Kaplan–Meier method. The curves were plotted and compared using the log-rank test using Prism 5.02 (GraphPad Software). The data from the limiting dilution assay were analyzed and plotted using ELDA software. The likelihood ratio test and χ² test were used to assess the significance.

Online supplemental material
Fig. S1 shows the gating strategy and flow cytometric analysis of CD44^CD24^low/− breast carcinoma cells. Fig. S2 shows the strategy and flow cytometric analysis of CD44^CD24^−/low carcinoma cells in PDX breast tumors. Fig. S3 shows the gating strategy and flow cytometric analysis of CD133^CD44^+PDAC cells. Fig. S4 shows the patterns of CD44 and CD133 staining of primary SP-1 cells in the cancer cell/PSC co-culture. Table S1 shows clinical characteristics of the breast tumors used for cell isolation and LCM experiments.

ACKNOWLEDGMENTS
This work was supported in part by grants from the Ministry of Science and Technology, Taiwan (MOST 102-2628-B-400-MY3, MOST 103-2314-B-400-019, MOST 104-2314-B-400-022-MY3, and MOST 105-2314-B-400-018-MY3 to K.K. Tsai), grants from the National Health Research Institutes, Taiwan (NHRI-EX100-1113B and NHRI-105-9124-M-002-007-MY3 to K.K. Tsai), grants from the US Department of Defense Breast Cancer Research Program (BC122900 to V.M. Weaver), a grant from Taipei Medical University, Wan Fang Hospital (104-wf-phd-01 to T.S. Chan), and grants from the National Cancer Institute at the National Institutes of Health, USA (RO1 CA174929 and CA192914-01 to V.M. Weaver). S.S. Huang conducted his thesis research under the auspices of the Graduate Program of Biotechnology in Medicine, National Tsing Hua University, and the National Health Research Institutes. The authors declare no competing financial interests.

Submitted: 22 October 2015
Revised: 8 June 2016
Accepted: 21 October 2016

REFERENCES
Fogli, S., R. Danesi, A. Gemmi, S. Donati, P.F. Conte, and M. Del Taccia. 2002. Geminibate, epirubicin and paclitaxel: pharmacokinetic and


Richardson, K. Polyak, R. Tubo, and R.A. Weinberg. 2007. Mesenchymal


